Litcius/Paper detail

Cabozantinib in patients with unresectable and progressive metastatic phaeochromocytoma or paraganglioma (the Natalie Trial): a single-arm, phase 2 trial

Camilo Jiménez, Mouhammed Amir Habra, Matthew T. Campbell, Gina Tamsen, Damaris Cruz-Goldberg, James P. Long, Roland L. Bassett, Robert Dantzer, Vania Balderrama-Brondani, Jeena Varghese, Yang Lü

2024The Lancet Oncology28 citationsDOI

Topics & Concepts

CabozantinibMedicineClinical endpointInternal medicineAdverse effectClinical trialAsymptomaticResponse Evaluation Criteria in Solid TumorsParagangliomaOncologyCancerPhases of clinical researchSurgeryAdrenal and Paraganglionic TumorsPituitary Gland Disorders and TreatmentsCancer, Hypoxia, and Metabolism
Cabozantinib in patients with unresectable and progressive metastatic phaeochromocytoma or paraganglioma (the Natalie Trial): a single-arm, phase 2 trial | Litcius